There is provided herein a process for the synthesis of sulfonyl silanes. There is also provided herein various sulfenylated and sulfonylated silicon-containing compounds made by the process.

Processes are described for purifying acidic, preferably superacidic, in particular trifluoromethanesulfonic acid-acidified, end-equilibrated acetoxysiloxanes, wherein the acidic, preferably superacidic, in particular trifluoromethanesulfonic acid-acidified, acetic anhydride-containing and optionally acetic acid-containing equilibrated, preferably end-equilibrated acetoxysiloxane, which is optionally dissolved in an inert solvent, is contacted with a base, the precipitate is filtered off thereafter and then the filtrate obtained is optionally purified by distillation.

A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof are provided. Specifically, provided herein are a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.

##STR00001##

Provided are a heterocyclic compound represented by Formula 1 below, an organic light-emitting device including the same, and an electronic apparatus including the organic light-emitting device:

##STR00001## wherein, Formula 1 is the same as described in the present specification.

The present invention describes chemical systems and methods for silylating aromatic organic substrates, said system or method comprising or consisting essentially of a mixture of (a) at least one organosilane and (b) at least one strong base, the definition of strong base now also including KOH, said system being preferably, but not necessarily substantially free of a transition-metal compound, and said methods comprising contacting a quantity of the organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate.

The present disclosure describes methods for silylating aromatic derivatives, comprising the use of hydrosilanes and potassium hydroxide.

The present application relates to a preparation method for a pyrrolopyrimidine compound, comprising: obtaining a compound 3 from a compound 2, obtaining a compound 4P2 from the compound 3, and obtaining a pyrrolopyrimidine compound of formula I by removing a protecting group from the compound 4P2. The preparation method of the present application has the advantages of simple operation, mild reaction conditions and high yield, avoids the problems of low yield and a large amount of impurities and difficult separation of same in original routes, reduces production costs, and is suitable for industrial production. Furthermore, the product yield of each step is high, and basically reaches about 80%, and even the yield of some steps can reach 90% or more.

##STR00001##

The present disclosure describes methods for silylating aromatic derivatives, comprising the use of hydrosilanes and potassium hydroxide.

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.

The present disclosure describes methods for silylating aromatic derivatives, comprising the use of hydrosilanes and potassium hydroxide.